Our list of outings for the year ahead includes a guided tour of Newbridge Silver and Kildare Village, a guided tour of Trinity College, the National Stud and Japanese Gardens, Dalkey Castle and a ...

He will look to get the Dragons back to the state title game and look for another championship, as the last time the New York high school won the title was in the 2018-19 season. Cornwall will ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in ...

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...

Durgan is an ideal setting to explore the uneasy relationship between Cornwall's past and present ... including the old school house. Cornish actor Michael Fenner plays the part of a fisherman ...

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the hyper-competitive market for obesity drugs. Morten Lammert will join Roche as its ...

A surf school in Cornwall has been left high and dry in the run-up to Easter after a trailer full of paddleboards was stolen. Robin Ross, from Freewave Surf Academy in Bude, said the box trailer ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...

Two months after U.S. President Donald Trump issued an executive order proclaiming diversity, equity and inclusion (DEI) programs “illegal and immoral,” Roche has scrapped its high-profile ...

Durgan is an ideal setting to explore the uneasy relationship between Cornwall's past and present ... 15 houses are owned and ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and ...